Literature DB >> 31343905

Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement.

Laura A Levit1, Jeffrey M Peppercorn2, Alda L Tam3, Jonathan M Marron4, Debra J H Mathews5, Kathryn Levit6, Nancy Roach7, Mark J Ratain8.   

Abstract

In contrast to clinical biopsies, where tissue is collected to inform patient care, research biopsies are performed for scientific purposes to potentially enhance understanding of the biologic bases of cancer and drug action, thereby improving diagnosis and treatment, but they may offer no direct benefit to participants and have known risks. The widespread use of research biopsies that do not have the potential to directly benefit participants has come under scrutiny, with critics raising ethical concerns related to the adequacy of participant protections, informed consent, and participant understanding of the risks and benefits, as well as the scientific impact of research biopsies on drug development and treatment. This manuscript presents the American Society of Clinical Oncology's (ASCO's) ethical framework for incorporation of research biopsies in trials. The framework provides guidance on the circumstances to include optional and mandatory biopsies, as well as provides recommendations to stakeholders on necessary steps for improving the conduct of research biopsies overall.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31343905     DOI: 10.1200/JCO.19.01479

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

Review 1.  Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.

Authors:  Abhijit Pal; Rajiv Shinde; Manuel Selvi Miralles; Paul Workman; Johann de Bono
Journal:  Nat Rev Clin Oncol       Date:  2021-03-24       Impact factor: 66.675

2.  Implications of Research Biopsies in Clinical Trials.

Authors:  Sarah M Dermody; Andrew G Shuman
Journal:  Oncologist       Date:  2021-08-31

Review 3.  Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data.

Authors:  Rumana Rashid; Yu-An Chen; John Hoffer; Jeremy L Muhlich; Jia-Ren Lin; Robert Krueger; Hanspeter Pfister; Richard Mitchell; Sandro Santagata; Peter K Sorger
Journal:  Nat Biomed Eng       Date:  2021-11-08       Impact factor: 29.234

4.  Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer Center.

Authors:  Nathalie Olympios; Laetitia Collet; Marianne Paesmans; Christiane Jungels; Nuria Kotecki; Ahmad Awada; Philippe Aftimos
Journal:  Oncologist       Date:  2021-08-04

5.  Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials.

Authors:  Jonathan H Cheng; Justin W Tiulim; Sheng Zhou; Anthony El-Khoueiry; Jorge Nieva
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

6.  Variability in biopsy quality informs translational research applications in hepatocellular carcinoma.

Authors:  Kelley Weinfurtner; Joshua Cho; Daniel Ackerman; James X Chen; Abashai Woodard; Wuyan Li; David Ostrowski; Michael C Soulen; Mandeep Dagli; Susan Shamimi-Noori; Jeffrey Mondschein; Deepak Sudheendra; S William Stavropoulos; Shilpa Reddy; Jonas Redmond; Tamim Khaddash; Darshana Jhala; Evan S Siegelman; Emma E Furth; Stephen J Hunt; Gregory J Nadolski; David E Kaplan; Terence P F Gade
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.996

7.  Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.

Authors:  Patricia LoRusso; Mark J Ratain; Toshihiko Doi; Drew W Rasco; Maja J A de Jonge; Victor Moreno; Benedito A Carneiro; Lot A Devriese; Adam Petrich; Dimple Modi; Susan Morgan-Lappe; Silpa Nuthalapati; Monica Motwani; Martin Dunbar; Jaimee Glasgow; Bruno C Medeiros; Emiliano Calvo
Journal:  Invest New Drugs       Date:  2022-04-25       Impact factor: 3.651

8.  Practical consideration for successful sequential tumor biopsies in first-in-human trials.

Authors:  Takafumi Koyama; Toshio Shimizu; Jun Sato; Yuki Katsuya; Satoru Iwasa; Shunsuke Kondo; Tatsuya Yoshida; Kazuki Sudo; Makoto Nishino; Yuichi Takiguchi; Kan Yonemori; Noboru Yamamoto
Journal:  Invest New Drugs       Date:  2022-04-11       Impact factor: 3.651

9.  An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.

Authors:  David C Madoff; Nadine Abi-Jaoudeh; David Braxton; Lipika Goyal; Dhanpat Jain; Bruno C Odisio; Riad Salem; Mark Schattner; Rahul Sheth; Daneng Li
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

10.  Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.

Authors:  Kamal S Saini; Begoña de Las Heras; Ruth Plummer; Victor Moreno; Marco Romano; Javier de Castro; Philippe Aftimos; Judy Fredriksson; Gouri Shankar Bhattacharyya; Martin Sebastian Olivo; Gaia Schiavon; Kevin Punie; Jesus Garcia-Foncillas; Ernesto Rogata; Richie Pfeiffer; Cecilia Orbegoso; Kenneth Morrison; Giuseppe Curigliano; Lynda Chin; Monika Lamba Saini; Øystein Rekdal; Steven Anderson; Javier Cortes; Manuela Leone; Janet Dancey; Chris Twelves; Ahmad Awada
Journal:  JCO Glob Oncol       Date:  2020-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.